Synapse - Works

Results (2146)

CA125 response to bevacizumab in recurrent ovarian cancer

Meeting Abstract

O'Cearbhaill, R. E.; Zhou, Q.; Iasonos, A.; Diaz, J. P.; Tew, W. P.; Hensley, M. L.; O'Flaherty, C.; Aghajanian, C.; Spriggs, D. R.; Sabbatini, P.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Immunohistochemical expression of ER and PR and outcomes in patients with newly diagnosed uterine leiomyosarcoma

Meeting Abstract

Leitao, M. M.; Hensley, M. L.; Barakat, R. R.; O'Cearbhaill, R.; Soslow, R. A.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Self-identification by Jewish religion: Lack of association with overall survival in ovarian cancer at Memorial Sloan-Kettering Cancer Center from 1998 to 2006

Meeting Abstract

Konner, J. A.; Iasonos, A.; Sabbatini, P.; Tew, W. P.; Hensley, M. L.; Aghajanian, C.; Kauff, N. D.; Moss, R. A.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Predicting chemotherapy toxicity in older adults with cancer: A prospective 500 patient multicenter study

Meeting Abstract

Hurria, A.; Togawa, K.; Mohile, S. G.; Owusu, C.; Klepin, H. D.; Gross, C.; Lichtman, S. M.; Katheria, V.; Klapper, S.; Tew, W. P.; more...
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Adjuvant treatment of high-risk primary uterine Ieiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005

Meeting Abstract

Hensley, M. L.; Wathen, K.; Maki, R. G.; Araujo, D. M.; Sutton, G.; Priebat, D. A.; George, S.; Baker, L. H.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer

Meeting Abstract

Elit, L.; Konner, J. A.; Armstrong, D. K.; Buck, M.; Dean, A.; Finkler, N. J.; Hulstine, A.; Schweizer, C.; Phillips, M.; Weil, S.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

A phase I study of NY-ESO-1 overlapping peptides with or without incomplete Freund's adjuvant and poly-ICLCL vaccination of ovarian cancer patients in second or third clinical remission

Meeting Abstract

Diefenbach, C. S. M.; Sabbatini, P.; Hensley, M. L.; Konner, J. A.; Tew, W. P.; Ritter, G.; Jungbluth, A.; Pan, L. S.; Old, L. J.; Gnjatic, S.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): First-in human clinical experience of a folate receptor-targeted chemotherapeutic agent administered on days 1, 4, 8, and 11 of a 21-day cycle

Meeting Abstract

De Jonge, M. J.; Sleijfer, S.; Martin, L. P.; Marshall, J.; Deeken, J. F.; Konner, L. A.; Aghajanian, C.; BMS Phase I Clinical Research Team
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Development of a performance status prediction model for use in administrative data analyses

Meeting Abstract

Davidoff, A. J.; Zuckerman, I. H.; Pandya, N. B.; Hendrick, F.; Ke, X.; Hurria, A.; Lichtman, S. M.; Hussain, A.; Edelman, M. J.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

A phase I dose escalation study of AGS-8M4 (ASP6183), an anti-AGS-8 fully human antibody, in advanced ovarian cancer

Meeting Abstract

Armstrong, D. K.; Herzog, T. J.; Reyno, L. M.; Vincent, M.; Jackson, L.; Sabbatini, P.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save